Kuchinja kwemajini eEML4-ALK eHuman Fusion

Kit iyi inoshandiswa kuona mhando gumi nembiri dzeEML4-ALK fusion gene mumasampuli evarwere vekenza yemapapu vasiri masero madiki mu vitro. Mhedzisiro yebvunzo ndeyekutarisa chete pakiriniki uye haifanirwe kushandiswa senzira chete yekurapa varwere vakasiyana. Vanachiremba vanofanirwa kuita sarudzo dzakakwana pamhedzisiro yebvunzo zvichibva pazvinhu zvakaita semamiriro emurwere, zviratidzo zvemishonga, mhinduro yekurapa, nezvimwe zviratidzo zvebvunzo yerabhoritari. Kenza yemapapu ndiyo bundu rinonyanya kuipa pasi rose, uye 80% ~ 85% yezviitiko ikenza yemapapu isiri masero madiki (NSCLC). Kusanganiswa kwemajini e echinoderm microtubule-associated protein-like 4 (EML4) uye anaplastic lymphoma kinase (ALK) chinhu chitsva muNSCLC, EML4 neALK zvinowanikwa muvanhu, P21 neP23 bands pachromosome 2 uye zvakaparadzaniswa nemamiriyoni gumi nemaviri nemazana manomwe ezviuru. Pane mhando dzinosvika makumi maviri dzekubatanidza dzakawanikwa, pakati padzo dzinenge gumi nembiri dzekubatanidza mutsauko muTafura 1 dzakajairika, uko mutant 1 (E13; A20) ndiyo inonyanya kushandiswa, ichiteverwa ne mutants 3a ne3b (E6; A20), inoverengera vanenge 33% ne29% yevarwere vane EML4-ALK fusion gene NSCLC, zvichiteerana. ALK inhibitors inomiririrwa neCrizotinib mishonga inotarirwa nemamorekuru madiki yakagadzirirwa ALK gene fusion mutations. Nekudzivisa kushanda kwenzvimbo yeALK tyrosine kinase, kuvharira nzira dzayo dzekutumira zviratidzo zvisina kujairika, nokudaro zvichidzivisa kukura kwemasero egomarara, kuti vawane kurapwa kwakanangana nemagomarara. Zvidzidzo zvekiriniki zvakaratidza kuti Crizotinib ine mwero unoshanda weanopfuura 61% muvarwere vane EML4-ALK fusion mutations, nepo isina kana simba pavarwere vemhando yemusango. Nokudaro, kuonekwa kweEML4-ALK fusion mutation ndiyo hwaro uye hwaro hwekutungamira kushandiswa kwemishonga yeCrizotinib.